Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-oriented pembrolizumab plus chemotherapy in chemotherapy-naïve advanced pancreatic cancer
KCT0005102Phase 2Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in pancreatic cancer (PC), sponsored by Seoul National University Hospital. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0005102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005102.